Literature DB >> 14684150

3D structure of the CD26-ADA complex obtained by cryo-EM and single particle analysis.

Kai Ludwig1, Hua Fan, Jörg Dobers, Markus Berger, Werner Reutter, Christoph Böttcher.   

Abstract

The specific binding of adenosine deaminase to the multifunctional membrane glycoprotein dipeptidyl peptidase IV is thought to be immunologically relevant for certain regulatory and co-stimulatory processes. In this study we present the 3D structure of the complete CD26-ADA complex obtained by single particle cryo-EM at 22A resolution. ADA binding occurs at the outer edges of the beta-propeller of CD26. Docking calculations of available CD26 and ADA crystal data into the obtained EM density map revealed that the ADA-binding site is stretched across CD26 beta-propeller blades 4 and 5 involving the outermost distal hydrophobic amino acids L294 and V341 but not T440 and K441 as suggested by antibody binding. Though the docking of the ADA orientation appears less significant due to the lack of distinct surface features, non-ambiguous conclusions can be drawn in the combination with earlier indirect non-imaging methods affirming the crucial role of the ADA alpha2-helix for binding.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14684150     DOI: 10.1016/j.bbrc.2003.11.112

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  2 in total

1.  Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody.

Authors:  Kei Ohnuma; Bart L Haagmans; Ryo Hatano; V Stalin Raj; Huihui Mou; Satoshi Iwata; Nam H Dang; Berend Jan Bosch; Chikao Morimoto
Journal:  J Virol       Date:  2013-09-25       Impact factor: 5.103

2.  Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses.

Authors:  Kalpit A Vora; Gene Porter; Roche Peng; Yan Cui; Kellyann Pryor; George Eiermann; Dennis M Zaller
Journal:  BMC Immunol       Date:  2009-04-09       Impact factor: 3.615

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.